RecruitingPhase 1NCT07535606

A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers

Sponsor

Alnylam Pharmaceuticals

Enrollment

44 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria1

Is willing and able to complete all study assessments

Exclusion Criteria4

Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >upper limit of normal (ULN)
Has total bilirubin >ULN
Has no history of invasive infection by an encapsulated organism
Has no known complement or immunologic deficiency

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGALN-4915

ALN-4915 will be administered subcutaneously (SC)

DRUGPlacebo

Placebo will be administered SC

Locations(1)

Clinical Trial Site

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07535606

Related Trials

Cytapheresis of Volunteer Donors

NCT001043251 location

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT000710451 location